Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations

BACKGROUND: In Central and South America and Eastern and Southern Africa, Plasmodium vivax infections accounts for 71-81% and 5% of malaria cases, respectively. In these areas, chloroquine (CQ) remains the treatment of choice for P. vivax malaria. In addition, CQ has recently proven to be an effecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalil, Insaf F, Alifrangis, Michael, Recke, Camilla, Hoegberg, Lotte C, Ronn, Anita, Bygbjerg, Ib C, Koch, Claus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170649/
https://www.ncbi.nlm.nih.gov/pubmed/21864375
http://dx.doi.org/10.1186/1475-2875-10-249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170649/
https://www.ncbi.nlm.nih.gov/pubmed/21864375
http://dx.doi.org/10.1186/1475-2875-10-249

Ejemplares similares